Corcept.

Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH).Dec 20, 2021 · Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ... Dec 5, 2023 · Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with ... Cortisol. Cortisol is a hormone that modulates many physiological and psychological processes. Because of its central role in the body’s response to stress, cortisol is most commonly known as the stress hormone. It plays a key role in regulating metabolism and maintaining normal blood pressure. It affects both cognition and emotional state.

Corcept believes that all employees should have the opportunity to participate in the company’s success. We offer competitive salaries, option grants, and a comprehensive benefits program, which covers 100 percent of the premiums for you and your dependents, including. Vacation, sick, and flex-time policies that foster strong work/life balance.Web

Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

MENLO PARK, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2022 financial results and provide a corporate update on February 28, 2023.The company will also host a conference call that day at 5:00 p.m. Eastern Time …Jun 30, 2022 · Corcept’s second quarter 2022 revenue was $103.4 million, compared to $91.6 million in the second quarter of 2021. Second quarter operating expenses were $72.0 million , compared to $59.6 million in the second quarter of 2021, due to increased clinical trial activity, expenses to support the expansion of our clinical development and ... Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone ...Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has …

9 Des 2022 ... To overcome these limitations, Corcept may have tried to increase this available market for Korlym by lowering diagnostic standards for ...

Cafepharma is a site for the pharmaceutical/medical industry. Our scope includes pharmaceutical, device, biotech, laboratory, animal health, dental, etc. We have curated daily news headlines, active forums where users can post anonymously, job listings and more.

About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with …Corcept Therapeutics overview Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym …A month has gone by since the last earnings report for Corcept Therapeutics (CORT). Shares have added about 0.7% in that time frame, underperforming the S&P 500. Will the recent positive trend ...Corcept prides itself on a dynamic culture which remains true to its values while embracing continued growth and change. Our work is marked by innovation, integrity, rigor, transparent communication, and collaboration. We all have unique contributions to make, and our success is the sum of those contributions. Join us!MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol, today announced that it has commenced a …Web

Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer.Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...WebCorcept Therapeutics overview Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym …Corcept Therapeutics announced the preliminary results of its previously announced tender offer to purchase up to 7,500,000 shares of its common stock, par value $0.001 per share, at a price not greater than $22.00 nor less than $19.25 per share, in cash, less any applicable withholding taxes and without interest, which expired one minute after ...Corcept Therapeutics Incorporated (. CORT Quick Quote. CORT - Free Report) reported third-quarter 2023 earnings of 28 cents per share, which beat the Zacks Consensus Estimate of 22 cents. The ...

Institutional Trading of Corcept Therapeutics. A number of hedge funds have recently added to or reduced their stakes in the stock. Diversified Trust Co acquired a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $254,000. Morgan Stanley lifted its position in Corcept Therapeutics by 31.9% during the 3rd quarter.WebMar 31, 2020 · About Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...

Corcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million , compared to $69.8 million in the third quarter of 2022, due to increased clinical trial activity and expenses to support the expansion of our clinical development and ...Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking Statements.WebAbout Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...Mar 6, 2023 · Corcept may not consummate the tender offer described in this press release and, if the tender offer is consummated, cannot provide any assurances regarding the final terms of the tender offer. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has …WebDec 31, 2021 · MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021. Eurofins's competitors and similar companies include Catalent, Labcorp Drug Development, Xencor and Corcept Therapeutics. Add company... Eurofins Scientific is a life sciences company providing laboratory testing services. Catalent is a company that develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies ...MENLO PARK, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat ...Web7 Okt 2022 ... Corcept Therapeutics Extends Exclusive Specialty Pharmacy Distribution Agreement for Korlym with Optime Care.Corcept's work represents a unique opportunity for a small biopharmaceutical company. The 240-person business has largely flown under the radar since 2012, when it won its first and only Food and ...

Under the proposed settlement, Corcept has agreed to make a one-time payment of $14.0 million, which will be covered in full by Corcept’s insurers. About Corcept Therapeutics

Apr 7, 2022 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ...

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, ...--Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncology, metabolism, and neurology disorders by ...Read Our Latest Stock Report on Corcept Therapeutics. Corcept Therapeutics Stock Performance. CORT stock opened at $25.97 on Monday. Corcept Therapeutics has a one year low of $17.86 and a one ...WebAbout Corcept Therapeutics. Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym ® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s ...Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and liver disease (NASH). In February 2012 , the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome.Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis ...WebCorcept’s third quarter 2023 revenue was $123.6 million, compared to $101.7 million in the third quarter of 2022. Third quarter operating expenses were $92.4 million , compared to $69.8 million in the third quarter of 2022, due to increased clinical trial activity and expenses to support the expansion of our clinical development and ...The Associate Director, Clinical Operations will provide expertise and oversight for multiple clinical trials or a clinical program to ensure the trials are conducted in accordance with the protocols, SOPs, GCP and departmental and corporate goals. This role will provide leadership and direction to the Clinical Operations teams in the ...Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park,... Read More. View Company Info for Free. Who is Corcept Therapeutics. Headquarters. 149 Commonwealth Dr, Menlo Park, California, 94025, United States. Phone Number (650) 327-3270. Website. www.corcept.com. Revenue. $380.2M.WebCorcept’s drug Korlym ® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Forward Looking StatementsWeb

The Associate Director, Clinical Operations will provide expertise and oversight for multiple clinical trials or a clinical program to ensure the trials are conducted in accordance with the protocols, SOPs, GCP and departmental and corporate goals. This role will provide leadership and direction to the Clinical Operations teams in the ...November 2023 – PROPRIETARY – Do not republish, redistribute or modify without Corcept’s express written permission This presentation contains forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended, and the Securities Act of 1933, as amended. Jul 17, 2023 · Corcept’s drug Korlym® was the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Instagram:https://instagram. webull option spreadsslyv etfis wall street prep worth ituecstock Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has …Web steps to start day tradingwebull paper money Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 14,120,000 shares, a decrease of 5.6% from the October 15th total of 14,960,000 shares. Currently, 16.1% of the shares of the stock are sold short.WebCorcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. The company is conducting clinical trials of its leading cortisol modulators ... canopy corp news Corcept Celebrates Hispanic Trailblazers During this Hispanic Heritage Month, we honor Dr. Bernardo Alberto Houssay (1887-1971), one of three Argentinians to receive the Nobel Prize in physiology ...Jun 30, 2023 · Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol and owns extensive United States and foreign intellectual property covering both their composition and their use to treat a variety of serious disorders. Clinical trials are being conducted with the company’s leading selective ...